Compare · NCEL vs NVO
NCEL vs NVO
Side-by-side comparison of NewcelX Ltd. (NCEL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NCEL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 10499.7x NCEL ($17.4M).
- Over the past year, NCEL is down 88.1% and NVO is down 45.7% - NVO leads by 42.5 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for NCEL).
- NVO has more recent analyst coverage (25 ratings vs 0 for NCEL).
- Company
- NewcelX Ltd.
- Novo Nordisk A/S
- Price
- $3.24-2.56%
- $41.01-4.51%
- Market cap
- $17.4M
- $183.15B
- 1M return
- -3.14%
- -10.44%
- 1Y return
- -88.13%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NCEL
- SEC Form 6-K filed by NewcelX Ltd.
- SEC Form 6-K filed by NewcelX Ltd.
- NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
- SEC Form EFFECT filed by NewcelX Ltd.
- SEC Form D filed by NewcelX Ltd.
- SEC Form F-3 filed by NewcelX Ltd.
- SEC Form EFFECT filed by NewcelX Ltd.
- SEC Form POS AM filed by NewcelX Ltd.
- SEC Form 6-K filed by NewcelX Ltd.
- NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care